N Chaithra, Jain Anisha, C Sahana, Shreevatsa Bhargav, Rajendrasozhan Saravanan, Dharmashekar Chandan, Suresh Kuralayanapalya Puttahonnappa, Patil Sharanagouda S, Singh Pranav, Vishwanath Prashant, Srinivasa Chandrashekar, Kollur Shiva Prasad, Shivamallu Chandan
Division of Medical Statistics, Life Sciences and Natural Sciences Departments, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Department of Microbiology, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Front Oncol. 2024 May 14;14:1298786. doi: 10.3389/fonc.2024.1298786. eCollection 2024.
Lung cancer is the foremost cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) accounting for 85-90% of cases. Targeted therapy is the most essential therapeutic option for NSCLC, other common treatments include radiation therapy, surgery, chemotherapy, and immunotherapy.
Our study objective was to estimate whether progression-free survival (PFS) is an outcome of NSCLC extracted from 18 randomized control trials (RCTs) with docetaxel as experimental group and antineoplastic agent, kinase inhibitor, and monoclonal antibodies as a control group.
We selected relevant studies published between 2011 and 2022 using Google Scholar, PubMed, Scopus, Science Direct, and Cochrane Library. Advanced NSCLC, chemotherapy, RCT, docetaxel, and second-line treatment were the terms included in the search. A total of 9738 patients were evaluated from the 18 identified studies. We used the meta package of R Studio to perform the meta-analysis. Graphical funnel plots were used to evaluate publication bias visually.
Patients who underwent docetaxel-based therapy had a considerably longer PFS than those who got antineoplastic agents, kinase inhibitors, or monoclonal antibodies-based treatment. Patients in the standard treatment arm had a slightly longer PFS than those in the experimental therapy arm in the overall meta-analysis.
Docetaxel outperformed monoclonal antibodies, antineoplastic agents, and kinase inhibitors in the second-line therapy of advanced NSCLC since PFS was extensively utilized.
肺癌是全球癌症相关死亡的首要原因，非小细胞肺癌（NSCLC）占病例的85 - 90%。靶向治疗是NSCLC最重要的治疗选择，其他常见治疗方法包括放射治疗、手术、化疗和免疫治疗。
我们的研究目的是评估无进展生存期（PFS）是否是从18项随机对照试验（RCT）中提取的NSCLC的一个结果，这些试验以多西他赛为实验组，以抗肿瘤药、激酶抑制剂和单克隆抗体为对照组。
我们使用谷歌学术、PubMed、Scopus、科学Direct和Cochrane图书馆选择了2011年至2022年期间发表的相关研究。搜索词包括晚期NSCLC、化疗、RCT、多西他赛和二线治疗。从18项已确定的研究中总共评估了9738名患者。我们使用R Studio的meta包进行荟萃分析。图形漏斗图用于直观评估发表偏倚。
接受基于多西他赛治疗的患者的PFS明显长于接受基于抗肿瘤药、激酶抑制剂或单克隆抗体治疗的患者。在总体荟萃分析中，标准治疗组的患者的PFS略长于实验治疗组的患者。
由于PFS被广泛应用，在晚期NSCLC的二线治疗中，多西他赛优于单克隆抗体、抗肿瘤药和激酶抑制剂。
